Trending...
- Georgia's Rainbow Village Launches Capital Campaign to More Than Double Its Capacity
- Green Office Partner Ranked #1 on Chicago Sun-Times' Best Workplaces List for 2024
- Retired Navy SEAL Launches Barrett Strategic Leadership Group (BSLG)
Patient-founded nonprofit seeks to stimulate innovative research to improve outcomes for patients with ROS1+ cancers.
SACRAMENTO, Calif. - GeorgiaChron -- The ROS1ders announced the recipient of the 2024 Eunice and Milton Ring Grant for ROS1 Cancer Research. Funding for this grant is provided by Eunice and Milton Ring, whose daughter Karen Ring Weiss is a member of the ROS1+ cancer community.
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on Georgia Chron
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Georgia Chron
About ROS1+ Cancer
The 2024 award was granted to Anthony Iafrate, MD, Ph.D, Professor of Pathology at Harvard Medical School and Vice Chair of Academic Affairs at the Massachusetts General Hospital. Dr. Iafrate's team is seeking new approaches to targeting ROS1+ fusion cancers that can overcome acquired resistance to current targeted therapies. They aim to identify regions of ROS1 fusion proteins that can be attacked with covalent inhibitors, which may lead to new treatments.
"Patient advocacy calls attention to the need for research about specific cancer biomarkers," says Eunice Ring. "Because ROS1+ cancer is rare, patients and their families must provide leadership in research focused on their cancer. We are very pleased to support Dr. Iafrate's team."
More on Georgia Chron
- Never-Before-Seen Kamala Harris and Ady Barkan Interview Released on Anniversary of Barkan's Passing, Just Ahead of Election Day
- OneVizion Announces Leadership Transition: Bradley Velotta Appointed as New President and CEO
- Rafflin Lepitre Champagnes Arrive in US
- Hoodgeek Merges Pov Commentary On Culture, Entertainment, Politics, Music, Sports, And Technology
- Boot Scootin' for Scholarships: A Night of Music, Dancing, and Giving Back!
This grant is the third in a series of seed grants focused on ROS1+ cancers. Janet Freeman-Daily, co-founder and president of the ROS1ders, says "Our ROS1+ cancer community is grateful that biomarker testing and targeted therapy have added years to so many lives. However, the currently approved drugs don't work well for everyone. We hope our seed grants will generate findings that lead to larger research efforts and better outcomes."
About the ROS1ders
Founded by patients, The ROS1ders is the largest global group of patients and family members living with ROS1+ cancer. It seeks to improve outcomes for all ROS1+ cancers through community, education, and research. Membership in their private Facebook group exceeds 1,100 people from over 30 countries. The nonprofit is internationally recognized in the oncology and patient advocacy communities as experts in their disease. Its resources include a medically-vetted website and collaboration with international ROS1+ clinicians, researchers and industry. Please visit theros1ders.org to learn more.
More on Georgia Chron
- Gov. Kemp Announces New Disaster Relief Measure for Georgia Farmers
- Player Play Date Atlanta Coming Up Next:
- Hufstetler Receives 'Champion of Georgia's Cities' Award
- Halloween is Out and Christmas is In! Brett Ryder is Kicking off the Holiday Cheer with his New Single "Countdown to Christmas"
- Alaskan Artist Builds Business to Fight Global Exploitation Through Fashion
About ROS1+ Cancer
- ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer (NSCLC). The incidence is thought to be similar in other types of cancer.
- Biomarker testing for ROS1 fusions is recommended in guidelines for non-small cell lung cancer, but currently for few other cancers.
- Patients are typically younger than the average NSCLC patient, have adenocarcinoma, and have no smoking history (a smoking history should not exclude patients from biomarker testing or targeted therapies).
- Oral targeted therapies are the recommended first-line treatment for metastatic ROS1+NSCLC and have increased the survival of patients by years. However, these drugs eventually stop working due to acquired resistance. The mechanisms of resistance are not well understood.
Source: The ROS1ders
Filed Under: Health
0 Comments
Latest on Georgia Chron
- TopCyberPro.com Founder and CEO Jim West Keynotes EC-Council Global CISO Forum
- SF Comedy Novel "Sex On the Wrong Brain" Claims Fascist Regimes Limit Reproductive Rights To Fuel Masturbation, Urges Simple Sex Ed Lesson
- OpenSSL Forms Business Advisory Committees: Shape the Future - Join Now!
- Last Chance for Green Card Dreams: DV Lottery Deadline Extended to November 7
- Advisors Mortgage Group Celebrates 25 Years of Building Dreams and Strengthening Communities
- SOVAS Honors the Legacy of James Earl Jones With the Newly Established "The James Earl Jones Prize"
- Nayarit Becomes An Official Tourism Destination of the Los Angeles Lakers
- David Weekley Homes Scored Nine Trophies at The 2024 Atlanta Obie Awards
- Nexgen Outfitters Secures GSA Contract, Bringing Premier Outdoor Sporting Goods and Equipment to Federal, State, and Local Agencies
- Onestreet Residential Closes On Hearthside Riverdale Site
- Trailblazing couple hosts first Black Men Buy Houses event in Atlanta expanding their 500 Black Men Buy Houses initiative
- Transform Your Date Night with Lick Pineapple Flavored Massage Oil – The Perfect Gift for New Relationships
- North Georgia Provisions Co. Launches Exquisite Winter Fragrance Line, Expands Local Presence
- Alessia Moccia of E-uphoria: Bridging Fashion, Art, and Technology in NYC
- The Nature Conservancy, Partners Protect Water for People and Nature with Landmark Easement
- Attorney Eric Chun Joins Bisnar Chase Personal Injury Attorneys, LLP
- Capital Realty Group Has An Outstanding October!
- Georgia's Rainbow Village Launches Capital Campaign to More Than Double Its Capacity
- The United States Environmental Protection Agency (USEPA) is SEBAC's 2024 Award for Excellence winner
- National Black Arts Festival Announces Cohort for Artist Project Fund